Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Maintenance Post-Allogeneic HCT for High-Risk Multiple Myeloma
NCT00847639Phase 2Completed
- Sponsor
- Center for International Blood and Marrow Transplant Research
- Start
- Feb 2009
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in multiple myeloma (MM), sponsored by Center for International Blood and Marrow Transplant Research. Started Feb 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00847639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00847639.